Needs of Medicare Beneficiaries with Mental Health Conditions

Back to Resources
ATIWork
07/27/2022
AUTHOR – ATI Advisory

Ensuring equitable and integrated care for beneficiaries with mental health conditions requires a whole-person approach. Recent bipartisan congressional interest in the behavioral health space signals that change is both necessary and coming.

Recent Work

Work

Opportunities for Improving Access to Palliative Care for Dual Eligible Individuals with Serious Illness

10% of dual eligible individuals report living with a serious illness, according to ATI Advisory’s (ATI) analysis of the 2018-2021 Medicare Current Beneficiary Survey (MCBS) using a narrow definition of serious illness. While this means that 10% of dual eligible individuals can potentially benefit from palliative care, much fewer actually receive such services. This brief highlights opportunities to promote access to palliative care for dual eligible individuals.
Read More Read More
Work

Health Equity Perspectives from Individuals Experiencing LTSS Needs, and their Caregivers, from Historically Marginalized Communities

ATI Advisory’s qualitative research highlights the experiences of individuals with long-term services and supports (LTSS) needs and their caregivers in requesting, receiving, and providing LTSS. Using a community-based participatory framework in partnership with local organizations, ATI conducted six focus groups interviewing individuals and caregivers from key populations across race, ethnicity, language ability, gender identity, sexual orientation, and disability status about their experiences with LTSS. Discussions generated themes around barriers to accessing LTSS, insights on family and professional caregiving across cultures, financial constraints, the value of social community for individuals and their caregivers, and the impacts of equitable and inequitable LTSS. This work was supported by the Robert Wood Johnson Foundation.
Read More Read More
Work

Pharmaceutical Innovation and the Inflation Reduction Act: 2023 in Review 

We’re back for our half-year check-in on pharma R&D, our first since CMS selected the first 10 drugs for Medicare negotiation. In this report, we examine how 19 of the largest biopharma companies approached investment in R&D, M&A, and licensing in 2023.
Read More Read More
See more Work
Share
LinkedIn / /